article thumbnail

Frost & Sullivan Awarded Duopharma Biotech with the 2022 Malaysian Company of the Year Award

Frost & Sullivan

SAN ANTONIO – July 27, 2023 – Frost & Sullivan recently researched the Malaysian biosimilars industry and, based on its findings, recognizes Duopharma Biotech Berhad (Duopharma Biotech) with the 2022 Malaysian Company of the Year Award.

Biotech 98
article thumbnail

Duopharma Biotech Applauded by Frost & Sullivan for Providing Innovative Healthcare Solutions in the Malaysian Market

Frost & Sullivan

SAN ANTONIO – July 25, 2023 – Frost & Sullivan recently researched the Malaysian halal pharmaceutical industry and, based on its findings, recognizes Duopharma Biotech Berhad (Duopharma Biotech) with the 2022 Malaysian Company of the Year Award.

Biotech 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biotech is Back to Work: JPM 2023 Week Wrap Up

LaVoie Health Science Blog

Here are the five key takeaways of the conference and what to expect as we come to the end the first month of the year: Biotech is Back: The COVID-19 pandemic caused a downturn for the biotech sector as whole, but JP Morgan Week showed a strong turnout, proving interest in both the science and investor sides of the industry.

Biotech 98
article thumbnail

A biotech survival kit for a challenging public-market environment

McKinsey & Company

After a decade of plenty, biotechs are grappling with a challenging market. To emerge strongly, they can streamline R&D and G&A expenses, evaluate new financing options, and consider mergers with other biotechs.

Biotech 86
article thumbnail

The UK biotech sector: The path to global leadership

McKinsey & Company

The United Kingdom is Europe’s leading biotech hub in breakthrough life-sciences start-ups. How is this hub maturing relative to its global peers, and what lies ahead on the road to sustainable scale?

Biotech 122
article thumbnail

What are the biotech investment themes that will shape the industry?

McKinsey & Company

From 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.

Biotech 117
article thumbnail

A new portfolio model for biotech

McKinsey & Company

An emerging model for biotech companies could disrupt the R&D landscape and open up new ways to invest, motivate teams, and shape the innovation pipeline.

Biotech 116